PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 4069333

Malignant carcinoid causing spinal cord compression.

G T Gowitt·S S Mirra
View original source ↗Export metadata ↓

Abstract

Neurological complications of malignant carcinoid are infrequent. Only 11 cases of central nervous system metastasis are documented, and neurological symptoms may be the initial or only manifestation of this tumor. We describe the case of a 60-year-old man with no known primary tumor who presented with spinal cord compression by a thoracic epidural tumor. After laminectomy, the diagnosis of carcinoid was made by light and electron microscopic demonstration of neurosecretory granules in tumor cells. Urine 5-hydroxyindole acetic acid and plasma serotonin levels were subsequently found to be elevated. Carcinoid tumors should be considered in the differential diagnosis of lesions metastatic to the spinal cord and brain.

Explore related subjects

Carcinoid TumorEpidural SpaceHumansMaleMiddle AgedMyelographySpinal Cord CompressionSpinal Cord NeoplasmsTomography, X-Ray ComputedCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G T Gowitt, S S Mirra. 1985. Malignant carcinoid causing spinal cord compression.. https://doi.org/10.1227/00006123-198511000-00013

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Solitary splenic metastasis of a carcinoid tumor of the lung eight years postoperatively.

The case of a 49-year-old male who was found to have a solitary splenic metastasis 8 years after undergoing right upper lobectomy for Stage 1 (pT1N0M0) bronchopulmonary carcinoid tumor and was treated by splenectomy is reported. Metastasis of bronchopulmonary carcinoid tumors to the spleen is very rare. However, it is important to bear in mind that there are patients with solitary splenic metastasis who have a favorable outcome.

Carcinoid Tumor↗
PubMed1998

Reduced uncertainty as a diagnostic benefit: an initial assessment of somatostatic receptor scintigraphy's value in detecting distant metastases of carcinoid liver tumours.

This paper employs classical concepts of diminishing marginal utility to demonstrate that risk-aversion can increase the perceived value of diagnostic procedures and thus raise optimum diagnostic expenditures. The theory is applied to a model in the spirit of Phelps and Mushlin's initial technology assessments. The specific evaluation is the cost-effectiveness of somatostatin receptor scintigraphy used to detect distant metastases of carcinoid liver tumours in a patient otherwise eligible for surgical resection of the liver. Data for the model are taken from published sources and financial databases, when available, and otherwise from a senior clinician's experience (LKK). The quantitative results indicate that receptor scintigraphy may have two beneficial impacts to risk-neutral individuals. First, it may reduce the combined costs of therapy and treatment because the diagnostic procedure costs less than the expected savings generated by avoiding inappropriate surgeries. Second, it may improve the patient's expected health-status-adjusted life years (HSALY) because the information allows physicians to better match treatment to the cancer's stage. Finally the paper demonstrates that risk aversion, as embodied in classical diminishing marginal utility applied to health status, can increase the value of the diagnostic tests and can lead the patient to choose a less beneficial treatment. An illustrative risk-averse utility function changed the optimum treatment from surgery to chemotherapy and increased scintigraphy's benefit by 500%.

Carcinoid Tumor↗